Active ingredients in most pharmaceutical products are complex organic molecules that require crystallization as a purification and isolation step that results in a pure product at a high process yield. Knowledge of the operating conditions required to obtain crystals with the desired crystal shape, polymorph, and morphology is critical during process development. This paper describes a two-stage mixed suspension mixed product removal (MSMPR) continuous reactive crystallization procedure developed for Aliskiren hemifumarate. This process was able to crystallize Aliskiren hemifumarate at both high purity (>99%) and high yield (>92%). A model of the crystallization was developed through the simultaneous solution of a population balance equation, kinetic expression for crystal growth and nucleation, and a mass balance. Experimental data were fit to the model to obtain kinetic parameters for crystal growth and nucleation. After including equilibrium distribution coefficient data, the model was used to optimize crystal purity and yield of the product by adjusting the operating temperature and residence time. This process has been integrated into an end-to-end continuous manufacturing system developed at MIT.

• Massachusetts Institute of Technology (MIT) (MIT)
• Tecnológico de Monterrey

• API

1. API
2. crystallization
3. Crystals
4. Impurities
5. Nucleation
6. Research Article
7. solubility